Asthma-chronic obstructive pulmonary disease overlap syndrome – Literature review and contributions towards a Portuguese consensus

D. Araújo , E. Padrão , M. Morais-Almeida , J. Cardoso , F. Pavão , R.B. Leite , A.C. Caldas , A. Marques
{"title":"Asthma-chronic obstructive pulmonary disease overlap syndrome – Literature review and contributions towards a Portuguese consensus","authors":"D. Araújo ,&nbsp;E. Padrão ,&nbsp;M. Morais-Almeida ,&nbsp;J. Cardoso ,&nbsp;F. Pavão ,&nbsp;R.B. Leite ,&nbsp;A.C. Caldas ,&nbsp;A. Marques","doi":"10.1016/j.rppnen.2016.11.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Phenotypic overlap between the two main chronic airway pulmonary diseases, asthma and chronic obstructive pulmonary disease (COPD), has been the subject of debate for decades, and recently the nomenclature of asthma-COPD overlap syndrome (ACOS) was adopted for this condition. The definition of this entity in the literature is, however, very heterogeneous, it is therefore important to define how it applies to Portugal.</p></div><div><h3>Methods</h3><p>A literature review of ACOS was made in a first phase resulting in the drawing up of a document that was later submitted for discussion among a panel of chronic lung diseases experts, resulting in reflexions about diagnosis, treatment and clinical guidance for ACOS patients.</p></div><div><h3>Results</h3><p>There was a consensus among the experts that the diagnosis of ACOS should be considered in the concomitant presence of: clinical manifestations characteristic of both asthma and COPD, persistent airway obstruction (post-bronchodilator FEV<sub>1</sub>/FVC<!--> <!-->&lt;<!--> <!-->0.7), positive response to bronchodilator test (increase in FEV<sub>1</sub> of ≥200<!--> <!-->mL and ≥12% from baseline) and current or past history of smoking or biomass exposure. In reaching diagnosis, the presence of peripheral eosinophilia (&gt;300<!--> <!-->eosinophils/μL or &gt;5% of leukocytes) and previous history of atopy should also be considered. The recommended first line pharmacological treatment in these patients is the ICS/LABA association; if symptomatic control is not achieved or in case of clinical severity, triple therapy with ICS/LABA/LAMA may be used. An effective control of the exposure to risk factors, vaccination, respiratory rehabilitation and treatment of comorbidities is also important.</p></div><div><h3>Conclusions</h3><p>The creation of initial guidelines on ACOS, which can be applied in the Portuguese context, has an important role in the generation of a broad nationwide consensus. This will give, in the near future, a far better clinical, functional and epidemiological characterization of ACOS patients, with the ultimate goal of achieving better therapeutic guidance.</p></div>","PeriodicalId":101122,"journal":{"name":"Revista Portuguesa de Pneumologia (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.rppnen.2016.11.005","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Portuguesa de Pneumologia (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173511516301385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Introduction

Phenotypic overlap between the two main chronic airway pulmonary diseases, asthma and chronic obstructive pulmonary disease (COPD), has been the subject of debate for decades, and recently the nomenclature of asthma-COPD overlap syndrome (ACOS) was adopted for this condition. The definition of this entity in the literature is, however, very heterogeneous, it is therefore important to define how it applies to Portugal.

Methods

A literature review of ACOS was made in a first phase resulting in the drawing up of a document that was later submitted for discussion among a panel of chronic lung diseases experts, resulting in reflexions about diagnosis, treatment and clinical guidance for ACOS patients.

Results

There was a consensus among the experts that the diagnosis of ACOS should be considered in the concomitant presence of: clinical manifestations characteristic of both asthma and COPD, persistent airway obstruction (post-bronchodilator FEV1/FVC < 0.7), positive response to bronchodilator test (increase in FEV1 of ≥200 mL and ≥12% from baseline) and current or past history of smoking or biomass exposure. In reaching diagnosis, the presence of peripheral eosinophilia (>300 eosinophils/μL or >5% of leukocytes) and previous history of atopy should also be considered. The recommended first line pharmacological treatment in these patients is the ICS/LABA association; if symptomatic control is not achieved or in case of clinical severity, triple therapy with ICS/LABA/LAMA may be used. An effective control of the exposure to risk factors, vaccination, respiratory rehabilitation and treatment of comorbidities is also important.

Conclusions

The creation of initial guidelines on ACOS, which can be applied in the Portuguese context, has an important role in the generation of a broad nationwide consensus. This will give, in the near future, a far better clinical, functional and epidemiological characterization of ACOS patients, with the ultimate goal of achieving better therapeutic guidance.

哮喘-慢性阻塞性肺疾病重叠综合征-文献综述和对葡萄牙共识的贡献
两种主要的慢性气道肺疾病,哮喘和慢性阻塞性肺疾病(COPD)之间的表型重叠,几十年来一直是争论的主题,最近哮喘-COPD重叠综合征(ACOS)的命名被采用。然而,文献中对这一实体的定义是非常不同的,因此重要的是要确定它如何适用于葡萄牙。方法对ACOS进行第一阶段的文献综述,并起草一份文件,提交慢性肺病专家小组讨论,对ACOS患者的诊断、治疗和临床指导进行思考。结果专家一致认为,在诊断ACOS时应同时考虑:哮喘和COPD的临床表现特征,持续气道阻塞(支气管扩张剂后FEV1/FVC <0.7),支气管扩张剂试验阳性反应(FEV1比基线增加≥200ml和≥12%),当前或过去有吸烟或生物质暴露史。在诊断时,还应考虑外周嗜酸性粒细胞(300嗜酸性粒细胞/μL或5%的白细胞)和既往特应性史。这些患者推荐的一线药物治疗是ICS/LABA联合;如果没有达到症状控制或临床严重,可以使用ICS/LABA/LAMA三联疗法。有效控制危险因素的暴露、疫苗接种、呼吸康复和合并症的治疗也很重要。关于ACOS的初步指导方针的创建,可以应用于葡萄牙的情况,对产生广泛的全国共识具有重要作用。这将在不久的将来为ACOS患者提供更好的临床、功能和流行病学特征,最终目标是实现更好的治疗指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信